Biotech IPO boom continues! Windward Bio (WWB.US) plans to raise US$185 million, betting on an antibody drug dosed once every six months.

date
21:21 09/11/2026
avatar
GMT Eight
Windward Bio Group is seeking a valuation of up to US$1 billion in its U.S. initial public offering (IPO). The company plans to offer approximately 10.3 million shares at a price range of US$16-18 per share to raise up to US$185.3 million.
Swiss clinical-stage biotech company Windward Bio Group plans to seek a valuation of up to US$1 billion in its U.S. initial public offering (IPO). The company said on Monday that it plans to offer approximately 10.3 million shares at a price range of US$16-18 per share to raise up to US$185.3 million. The company will list on Nasdaq under the ticker symbol "WWB." As turbulent market conditions and rising borrowing costs weigh on IPO activity in other sectors, biotech IPOs have become an important pillar of the U.S. IPO market this autumn. In addition to Windward Bio, drug developer Rezera also launched its U.S. IPO roadshow last week and is expected to list in New York this week. Windward Bio has secured US$310 million in equity financing from Novo Holdings, an affiliate of Novo Nordisk A/S Sponsored ADR Class B (NVO.US), and other healthcare investors, including OrbiMed, Blue Owl and RTW Investments. Information shows that Windward Bio is developing ultra-long-acting antibody drugs for the treatment of asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis, aimed at reducing dosing frequency. Its main candidate drug WIN378 targets TSLP, the same target as the approved drug Tezspire, with the difference being dosing frequency: WIN378 is designed to be administered once every six months, while Tezspire is administered once every four weeks. The company is currently conducting a Phase 2/3 clinical trial of WIN378 in severe uncontrolled asthma and a Phase 2 clinical trial in COPD; primary results from the asthma Phase 2 trial are expected in the first half of 2027. The company's second candidate drug WIN027 is a bispecific antibody targeting TSLP and IL-13. It is in Phase 1 clinical trials, and the company plans to initiate enrollment in Phase 2 clinical trials for COPD and atopic dermatitis in the first half of 2027. The company's core pipeline mainly comes from licensing deals with Chinese pharmaceutical companies the company has obtained licensing rights for WIN378 from Kelun-Biotech and Harbour BioMed, and licensing rights for WIN027 from Qyuns Therapeutics.